New standard of care? FDA hands Pfizer, Merck KGaA an OK for Bavencio in bladder cancer
The breakthrough therapy designation Pfizer and Merck KGaA notched for Bavencio in bladder cancer has quickly paved way for a full approval.
The PD …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
